
Gaurav Chatterjee
@gaurav_c42
Hematopathologist @ACTREC_TMC @TataMemorial. @India_Alliance Intermediate fellow. Genomics. ctDNA. Instrumental. Love Riva, Kajari and Freedom.
ID: 1187949993673379841
26-10-2019 04:32:14
913 Tweet
781 Takipçi
544 Takip Edilen

I am thrilled to share our new publication in @eClinicalMedicine co-led with a superb Vanderbilt Health IM resident James Brogan: "Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis" sciencedirect.com/science/articl… We analyzed 805,249 participants

🚨🚨Paper out! 🚨🚨 Delighted to share our work, now published in Nature Genetics 🧬! shorturl.at/94s5S We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n 🧵👇



🚨 We're Hiring: Research Scientist II 📍 Location: ACTREC–TMC, 🇮🇳 💰 Pay: ₹87,100/month 📅 Apply by: 16th July 2025 📧 Send your CV + supporting documents to: [email protected] Ad Details: tinyurl.com/4hr5z5hx



📣 Cell developmental state matters in B-ALL. Our study out today in Nature Cancer: Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features | Nature Cancer nature.com/articles/s4301…

🚨 New paper in Nature Genetics ! How does cancer chemotherapy reshape the HSC landscape and drive the evolution of therapy-related myeloid neoplasms? We uncovered this process through single-colony WGS! See the full paper here! nature.com/articles/s4158…




Just published in The ASCO Post My reflections from ICML 2025 — where lymphoma history met its future. From COO giving way to molecular clusters, to the TME guiding CART outcomes, to the undeniable momentum in aggressive B-cell lymphoma 👉 ascopost.com/news/july-2025… #ICML2025 #lymsm

Just published: on behalf of the European LeukemiaNet, the international expert panel led by Prof Jane Apperley presented the 2025 management recommendations of chronic myeloid leukemia (CML) in LEUKEMIA Leukemia Journal open access. nature.com/articles/s4137…

🔥 Cyclophosphamide (high dose) - for refractory ICANS post CAR-T from Tata Memorial Hospital Rahul Banerjee, MD, FACP Nikita Mehra 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM Rahul Purwar Ranjit Kumar Sahoo Gaurav Narula MD Prashant Mehta Dr Amol Akhade onlinelibrary.wiley.com/doi/10.1111/bj…

Just published in CancerMedicine 15 years of PBSC mobilization experience in Myeloma Even in the CAR-T era, collecting sufficient PBSCs is crucial. - GCSF+plerixafor comparable to chemo mobilization - If prior RT (to hematopoietic sites - spine, pelvis), chemo-mobn is better


*New Open-Access Long Read Resource*. We sequenced 1,019 genomes from the 1000 Genomes Project sample cohort using Oxford Nanopore. Sequencing data is available at bit.ly/4m8dlE2. EMBL Heinrich-Heine-Universität Düsseldorf IMP Centre for Genomic Regulation (CRG) nature.com/articles/s4158… [1/8]

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…


The BMRD #flowcytometry workshop at ACTREC-TMC is off to a great start with amazing talks from Pgs_mani , Orfao Lab and Sweta Rajpal . Lot of insightful discussions and revelations, in a packed hall! THE CYTOMETRY SOCIETY
